Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade

Next Previous
Trial Profile

UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin-2 (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Jan 2026 Planned End Date changed from 1 Dec 2023 to 1 Feb 2026.
  • 29 Jan 2026 Status changed from recruiting to active, no longer recruiting.
  • 06 Apr 2023 Planned End Date changed from 1 Jul 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top